Daniel Mark

All posts by Daniel Mark

RSS

March 23rd, 2015

Putting PROMISE in Greater Context

and

The PROMISE trial, which was presented and discussed in a Journal Club forum at ACC.15, prompted some interesting discussion when CardioExchange covered it as a news story on March 14. Dr. Daniel B. Mark, one of the PROMISE investigators, now sheds further light on the trial in response to questions from CardioExchange news writer Larry Husten. […]


April 9th, 2013

The TACT Investigators Respond to Questions

, , , , and

The publication in JAMA of the NIH’s Trial to Assess Chelation Therapy (TACT) has reignited a heated debate about the trial. The TACT investigators have generously agreed to respond to questions posed by Harlan Krumholz.


August 6th, 2012

TAVR and the Price of Innovation

, and

In an article published in Circulation, Daniel Mark and Robert Mentz of the Duke Clinical Research Institute and University Medical Center examine the economic and policy implications of the recent validation of transcatheter aortic valve replacement (TAVR) in the PARTNER trials. CardioExchange is fortunate and pleased to present Dr. Mark’s responses to questions about his […]